A new, predominantly single chain preparation of recombinant tissue-type plasminogen activator was evaluated to determine coronary thrombolytic efficacyin 100 patients with acute myocardial infarction. At 3.6 ± 1.2 hours (mean ± SD) from symptom onset, patients received either intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours) or placebo on a 3:1 randomized, double-blind basis. Coronary angiography, performed 68 ± 13 minutes after initiation of the study drug infusion, demonstrated patency of the infarct-related artery in 40 (57%) of 70 patients in the tissueplasminogenactivator group compared with3 (13%) of 23 patients in the placebo group (p < 0.001). Patients in the placebo group were then eligible to receive intracoronary streptokinase. At 90 minutes the patency was observed in 49 (69%) of71 tissue plasminogen activator patients compared with 5 (24%) of 21 placebo patients
A new, predominantly single chain preparation of recombinant tissue-type plasminogen activator was evaluated to determine coronary thrombolytic efficacyin 100 patients with acute myocardial infarction. At 3.6 ± 1.2 hours (mean ± SD) from symptom onset, patients received either intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours) or placebo on a 3:1 randomized, double-blind basis. Coronary angiography, performed 68 ± 13 minutes after initiation of the study drug infusion, demonstrated patency of the infarct-related artery in 40 (57%) of 70 patients in the tissueplasminogenactivator group compared with3 (13%) of 23 patients in the placebo group (p < 0.001). Patients in the placebo group were then eligible to receive intracoronary streptokinase. At 90 minutes the patency was observed in 49 (69%) of71 tissue plasminogen activator patients compared with 5 (24%) of 21 placebo patients
With the introduction of cell culture-derived tissue-type plasminogen activator, clot-selective thrombolysis became possible on a pilot scale (1-5). Recombinant DNA techniques allowed amplification of production, enabling large-(p < 0.001). At 120 minutes patency was observed in 59 (79%) of 75 patients of the tissue plasminogen activator group and in 10 (40%) of 25 in the intracoronary streptokinase/placebo group.
A nadir value of <100 mg/dl fibrinogen occurred in 8 (11%) of 73 patients receiving tissue plasminogen activator versus 8 (40%) of 20 patients treated with intracoronary streptokinase (p =0.002). Moderate or severe bleeding episodes occurred in 39% of patients treated with tissue plasminogen activator compared with 32% of patients who received placebo/intracpronary streptokinase (p = NS). Thus, this tissue plasminogen activator preparation achieves a high rate of recanalization and, at the doses employed, exhibits increased fibrinogen sparing compared with intracoronary streptokinase.
oAm Coli CardioI1987; 9:120S-13) scale clinical investigation. The first preparation of recombinant tissue plasminogen activator produced on a small scale for initial clinical testing was predominantly a twochain form (G 11021) because of cleavage at the molecule's arginine-275-isoleucine 276 peptide bond. Although several clinical studies in acute myocardial infarction have demonstrated the efficacy of tissue plasminogen activator G 11021 (6) (7) (8) (9) (10) , clot selectivity at moderate doses (~80 mg) was relative rather than absolute (11, 12) .
A new recombinant tissue plasminogen activator (G11035), manufactured on a large scale for clinical use, was found to be predominantly single chain (Genentech data on file). The focus of this study was to evaluate the coronary thrombolytic efficacy of this new tissue plasminogen activator preparation in a randomized, double-blind, placebo-con- 
Methods
Patient selection. This study was conducted at four centers with respective institutional review board approval. Patients were enrolled during a 5 month period, between September 1985 and February 1986. Inclusion criteria were: 1) chest discomfort longer in duration than 20 minutes and shorter than 6 hours and unresponsiveness to sublingual nitroglycerin; and 2) electrocardiographic (ECG) ST segment elevation of > 1 mm in two contiguous leads. Patients were excluded if they presented with cardiogenic shock or had had previous coronary artery bypass surgery, a prior transmural infarct in the same myocardial territory, recent «3 months) head trauma or stroke, major surgery in the past 2 weeks or a history of a bleeding diathesis.
During the study, a total of 109 patients met entry criteria. Of these, nine were excluded, four because a catheterization laboratory was unavailable, three because they refused to participate, one because there was no suitable vascular access site and one because of an episode of hemoptysis just before entry.
Protocol. Patients at each institution were randomized on a 3:1 basis to either tissue plasminogen activator or placebo, respectively. The study medication was administered on a double-blind basis as soon as informed consent was obtained. The dose of intravenous tissue plasminogen activator was 0.75 mg/kg body weight over the first hour with 10% given as a bolus, and 0.25 mg/kg per h over the subsequent 2 hours. A total maximal dose of 105 mg of tissue plasminogen activator was given even though 32 patients who were randomized to this agent weighed >80 kg. Using a single wall needle puncture and the Judkins technique, coronary arteriography of the infarct-related vessel was performed serially at 60, 90 and 120 minutes after initiation of the study drug infusion. At the first angiogram, performed at least 60 minutes into therapy, the infarct-related vessel patency status, classified according to the thrombolysis in myocardial infarction (TIMI) grading system (8) , was determined and the randomization code was broken to determine whether the study drug was tissue plasminogen activator or placebo.
As defined by the TIMl study group (8) . TIMI grade 0 = "no perfusion" with no anterograde flow beyond the point of occlusion; TIMI 1 = "penetration without perfusion" such that contrast agent fails to opacify the coronary bed distal to the obstruction; TIMI 2 = "partial perfusion": contrast filling is delayed or its clearance is delayed, but contrast material opacifies the distal coronary bed; and TIMI 3 = "complete perfusion": a normal pattern of contrast filling and clearance (8) .
Those patients with persistent occlusion who had received placebo were eligible to receive intracoronary streptokinase (a 20,000 U bolus and 2,000 to 4,000 Ulmin over 60 rninutes). Patients initially randomized to tissue plasminogen activator or placebo who manifested hemodynamic deterioration (systolic blood pressure <90 mm Hg, requirement for vasopressors) during the course of therapy were considered for emergent coronary angioplasty.
After the 120 minutepoint. patients were treatedas clinically indicated; coronary angioplasty was performed immediately (at 120 minutes of thrombolytic therapy) in 64 patients on the basis of experience and availability at each particular clinical site. Successful angioplasty was defined as <50% residual coronary stenosis and a normal flow (TIMI 3) pattern after completion of the procedure. One patient underwent emergency coronary artery bypass surgery for significant left main coronary artery stenosis. All patients were maintained on intravenous heparin, with 5,000 U given after arterial access and a continuous infusion of 800 to 1,000 U/h to keep the activated partial thromboplastin time at 1Yz to 2 times that of the control value. Patients received intravenous lidocaine (1 mg/kg bolus and a 2 to 4 mg/min infusion) for the first 24 hours.
Hematologic and bleeding evaluation. Blood samples were collected for the assay of coagulation and fibrinolytic components before and 45 minutes, 2 and 6 hours and 1 and 7 days after the beginning of the infusion. Blood was centrifuged within 1 hour and plasma frozen immediately. All assays were performed centrally in the thrombolysis core laboratory at the University of Vermont, Burlington. Plasma fibrinogen levels were measured in plasma samples obtained from blood collected on 0.01 M citrate (final concentration) and 200 kll.l/rnl aprotinin (Trasylol). Fibrinogen levels were measured by both a coagulation rate assay (13) and a sodium sulfite precipitation (14) ; fibrinogen-fibrin degradation products (fdp) were assayed by the tanned red cell agglutination inhibition method (15) . Plasminogen was determined on citrated plasma with the chromogenic substrate S-2251 after conversion to plasminogen-streptokinase complex, according to the instructions of the manufacturer (Kabi Vitrum). Tissue plasminogen activator antigen levels were measured on plasma samples collected on 0.01 M citrate as previously described (16) and factor V and factor VIII levels were determined, also as previously described (17) .
Bleeding wascharacterized by site and qualified as minor if it had no clinical consequence, moderate if greater than that usually observed in the clinical setting but with <250 ml estimated blood loss and severe if the blood loss was >250 ml, required transfusion or was retroperitoneal or intracranial. In patients receiving transfusion, the indication was determined. In some patients who received transfusion, there was no explanation (observed blood loss) for a sig- Coronary angioplasty and follow-up arteriography.
A flowchart for infarct-related vessel statu s and triage to immediate coronary angioplasty is shown in Figure 2 . Among the 75 patients receiving tissue plasminogen activator, 12 of the 16 patients who failed to demon strate infarct vessel patency underwent coron ary angioplasty after 120 minute s of infusion . In two of these , the procedure was unsucce ssful and three patients demonstrated reocclu sion on follow-up arteriography . Among the 59 patients who demon strated patenc y after tissue plasminogen activator therapy, 34 had acute angioplasty of the infarct-related artery. In 30 (88%) of the 34, the procedure was succe ssful (residual steno sis <50% and TIMI grade 3 recanalization Infarct-related vessel patency. Relevant clinical and baseline angiographic data are summarized in Table I . Infarct-related vessel patency of TIMI grade 2 or 3 (8) By this time four patient s in the placebo/streptok inase group had undergone coronary angioplasty because of hemodynamic deterioration. At 120 ± 4 minutes, 59 (79%) of 75 tissue plasm inogen activator treated patient s and 10 (40%) of 25 placebo/streptokinase patients had demon strated patency (p < 0 ,001 ).
The denominator of infarct vessel patency as expre ssed for each interval repre sents the total number of patients who had angiography performed at that time . A small number of patients in both groups did not have angiography at the 60 or 90 minute point becau se of difficultie s in obtain ing access or the delay of interhospital transport. Intermittent patency and occlusion during serial (60,90 and 120 minutes) recurrent ischemia and underwent coronary artery bypass grafting, and two had unsuccessful angioplasty without complications. The results for combined t-PA and coronary angioplasty are shown in Figure 3 .
In the placebo/streptokinase group, 17 of 21 patients received intracoronary streptokinase for persistent TIMI grade oor 1 flow (Fig. 2) . Of these, 6 (35%) exhibited recanalization within 1 hour after the initiationof streptokinase and 16 of the 21 underwent acute coronary angioplasty. Angioplasty was successful in achieving or augmenting recanalization in 14 (88%) of the 16 patients.
In seven patients who did not undergo angioplasty immediately, including one whose artery reoccluded and recanalized after repeat dosing of t-PA, this procedure was performed later because of postinfarction ischemia. The follOW-Up arteriographic data are incomplete with an overall 66% of patients (63 of 95 surviving patients) undergoing repeat study. The incidence rate of late (7 ± 3 days) angiographically documented infarct vessel patency was 73% (19 of 26) in patients with combined therapy (tissue plasminogen activator-mediated patency and immediate angioplasty) versus 64% (16 of 25) in those patients who dernonstrated patency with tissue plasminogen activator but did not undergo coronary angioplasty (p = NS).
Clinical outcomes. Death occurred in five patients in the trial, all within 48 hours of hospital admission. In the two placebo group patients who died, cardiogenic shock was present by the 90 minute point of infusion and recanalization with coronary angioplasty was subsequently unsuccessful . One patient had a proximal right coronary artery occlusion and the other a left anterior descending coronary artery occlusion with underlying severe three vessel coronary artery disease. Failure of tissue plasminogen activator to achieve proximal left anterior descending artery reperfusion occurred in two of the three patients who died in the tissue plasminogen activator patientgroup. The other patient had tissue plasminogen activator-mediated reperfusion and coronary angioplasty but sustained a massive anterior infarction and developed cardiogenic shock 8 hours after admission. There have been no furtherdeaths at a mean followup time of 5.5 ± 2 months.
Postinfarction ischemia, documented by recurrent chest pain and ECG changes, occurred in patients in the 12 tissue plasminogen activator group and 2 in the placebo group (p 
= NS). In four other patients, reinfarction was confirmed
by recurrent enzymatic creatine kinase , MB fraction elevation . The incidence of reinfarction was not different in the two treatment groups ( Table 2) . Angiographic confirmation of reocclusion was made in 12 (24%) of 51 tissue plasminogen activator-treated patients versus 3 (25%) of 12 placebo group patients who underwent repeat angiography (p = NS). Thus, subclinical or " silent" reocclu sion occurred in at least eight patients (8%) in the trial . Table 2 presents data on conge stive heart failure , defined as a new requirement for digoxin and furosemide therap y; pericarditis, defined as the presence of a friction rub and pleuritic chest pain; referral for coron ary artery bypass surgery ; and arrhythmias noted during or after therap y.
Bleeding and hemostatic function. Most of the bleeding complic ations in this trial were periaccess and overall these were more prevalent among patients treated with tissue plasminogen activator. Significant bleeding complications occurring in the first 72 hours after initiation of therapy are shown in Table 3 . A severe periaccess hemorrhage in one placebo group patient resulted in hypoten sion and transfusion of 6 units of packed red cells. One patient who underwent emergency coronary artery bypass grafting after receiving tissue plasminogen activator, developed a posterior fossa intracran ial hemorrhage 48 hours later. The hematom a was evacuated and the patient had no residual neurologic deficit. The 48 hour hiatus from tissue plasminogen activator therapy and the interpo sition of open heart surgery make it unlikely that the intracranial hemorrh age was secondary to fibrinolytic therapy . In the other two patients who underwent emergency bypass surgery , there were no significant bleeding complications and no transfusion was required.
Transfusion of one or more units of blood was given to 22 (29%) of 75 patients receiving tissue plasminogen activator and 4 ( 16%) of 25 receiving placebo (p = NS). In the tissue plasminogen activator group , blood was given to 4 patients as part of coronary artery bypass surgery , to 14 to augment hematocrit (in absence of evident blood loss), and to 4 to replace acute blood loss. In the placebo/streptokinase patient group , one patient received blood to replace periaccess bleeding and the other three for hematocrit augmentation . The baseline and nadir hematocrit values for the two group s of patients were not significantly differen t: tissue plasminogen activator baseline 43 ± 5.3%, nadir 35.5 ± 4.7%; placebo baseline 43 ± 4%, nadir 36 ± 4. 3% (p = NS). Similarl y, the platelet count decreased approximately 25% in both patient group s: tissue plasminogen activator baseline303 .4 ± 89,000 , nadir 230 ± 71,000; placebo baseline 304 ± 53,000 . nadir 228 ± 45 ,000 (p = NS). 
Discussion
Thrombolytic efficacy. We have demonstrated the efficacy of this predominantly single chain form of tissue plasminogen activator (GII 035) in achieving infarct vessel recanalization compared with placebo. Previous placebocontrolled trials of thrombolytic therapy (6, 10) have demonstrated a similarrate of ' 'spontaneous" thrombolysis, that is, approximately 20% of untreated patients demonstrating a patent infarct vessel on early angiography. The patency rates of 69% at 90 minutes and 79% at 120 minutes also compare favorably with the data from previously published trials (6) (7) (8) (9) (10) 18 ) which used the two-chain form of intravenous tissue plasminogen activator (G11021) ( Table 5) . Although over time after the initial angiogram , thrombolytic efficacy appeared to increase (57% at 60 minutes, 74% at 120 minutes) in tissue plasminogen activator-treated patients, this phenomenon could not be controlled for in placebo-treated patients. Serial intracoronary contrast injections, by transmission of the force of injectionand potential vasodilatory effects of contrast medium itself, may promote increased patency over time.
fibrinogen value at 45 minutes or 2 hours (r = -0 .0 1 and -0.16, respectively).
Samples from 62 patients drawn at baseline and between 7 and 47 (mean 22) days after treatment(223 samples) were evaluated for the development of antibody to tissue plasminogen activator. A positive tissue plasminogen activator antibody test, performed on day 7, occurred in only one patient. Repeat tests in this patient at 12 and 19 days after treatment were negative. The results of fibrinogen assays for the three patient groups are shown in Figure 4 . The results for the two assay methods were comparable; the sodium sulfite precipitation data are plotted (Fig. 3) . Relevant coagulation and fibrinolytic protein data are presented in Table 4 . Tissue plasminogen activator antigen and antibody. In the patients receiving tissue plasminogen activator, the baseline tissue plasminogen activator antigen level was 16 ± 8 ng/ml, which rose to 3,400 ± 1,600 ng/ml at 45 minutes and by 2 hours of infusion the level had fallen to 1150 ± 550 ng/ml. There was no correlation observed between tissue plasminogen activator antigen level and plasma
Figure4. Effects ofthree different therapies onplasma fibrinogen. The mean percent baseline fibrinogen plotted (standard deviation is reported in text) versus time is reported from onset of infusion for the patients treated with tissue plasminogen activator (rt-PA) (n = 71), intracoronary streptokinase (SK) (n = 20) or placebo (n = 4). There was no significant difference in the nadir of fibrinogen for the rt-PA and streptokinase treatment groups. Role of coronary angioplasty. The precise role of coronary angioplasty after intravenous thrombolytic therapy remains unclear. Although coronary angioplasty was not performed on a randomized basis in this multicenter trial, two interesting observations can be made about the impact of this technique on infarct vessel patency. First, in cases of persistentocclusion the technique was successful in 88% of patients. However, in those patients whose occluded vessel failed to recanalize after tissue plasminogen activator therapy, the long-term patency was reduced to only 50% of those undergoing repeat study. Patientswho do not respond to t-PA therapy are a very important subset because it is precisely this group that stands to benefit the most from urgent coronary arteriography and consideration for angieplasty. If failure to respond to tissue plasminogen activator predicts an unfavorable response for coronary angioplasty, the need for emergency cardiac catheterization may be lessened.
The second intriguingobservation about coronary angioplasty is the relatively high rate of late reocclusion (7 [18%] of 40) , despite initialsuccess, Previous studies (19-2 1) have suggested a 10 to 16% incidence of reocclusion after angioplasty in acute myocardial infarction. The explanation for lack of sustainedpatencyafter mechanical recanalization and use of concurrent antiplatelet and anticoagulation therapy remainsto be elucidated. It is likely that residual thrombus at the site of the initial plaque rupture or high grade stenosis plays a role. Other potential etiologic factors include vasospasm, balloon-induced intimal disruption or reperfusion injury with attendant decrease in flow.
Clinical outcome. The clinical outcomes for the two groups of patients in this trial were relatively similar. In light of the recent Italian randomized streptokinase (GISSI) trial in acute myocardial infarction (22) , it is clear that a large sample size and early treatment are required to dernonstrate reduction in mortality and improvement in clinical outcome with the use of early intravenous thrombolytic therapy (23) . Although therapy with intravenous tissue plasminogen activator was initiated at 3.6 ± 1.2 hours from the onset of symptoms, reperfusion was not obtainedbefore 4 .5 hours in most of the patients who demonstrated arteriographic patency.
Bleeding and hemostatic function. The bleedingresults in this trial are similar to those observed in previous studies (6) (7) (8) (9) (10) 18) of tissue plasminogen activator in acute myocardial infarction. It is difficult to attribute the frequency of periaccess bleeding to tissue plasminogen activator alone. Indeed, such patients are treated concomitantly with intravenous heparin, undergo invasive punctures for access during the cardiac catheterization and typically receive antiplatelettherapy. Substantiatingthe importanceof theseother factors , a recent study (24) in patients with myocardial infarction treated with direct coronary angioplasty showed no difference in bleeding in this group compared with that in patients receiving high dose intravenous streptokinase and angioplasty. Thus. tissue plasminogen activator is only one of several factors that promote bleeding in this clinical setting. Although fibrinogen decreased to a nadir of 66% after tissue plasminogen activator administration in our study, the value decreased below 100mg/dl in only eight patients. Intracoronary streptokinase (25) resulted in significant fibrinogen depletion, despite the low dose utilized and a low rate (33%) of thrombolytic efficacy. In 40 % of patients, intracoronary streptokinase led to a nadir fibrinogen value of < 100 rng/dl and recent studies (26) suggest that this profound depletion is a prerequisite for coronary thrombolysis.
The discrepancy between the fibrinogen-sparing nature of tissue plasminogenactivator and the need for transfusions in this group of patients in the trial is apparent. Despite the relative lack of fibrinogen depletion and breakdown, tissue plasminogen activator is an extremely potent fibrinolytic (rather than fibrinogenolytic) agent. Thus, periaccess and gastric mucosal sites may be at particular risk for increased bleeding during tissue plasminogen activator infusion. The heightened fibrinolytic efficacy of tissue plasminogen activator compared with that of streptokinase has been previously documented (8, 9) and it follows that unsuspected sites of preformed fibrin may be more susceptible to lysis with tissue plasminogen activator. However, this would be anticipated chiefly during the infusion, particularly during the high dose administered in the first hour. The marked variability in peak plasma t-PA antigen level has been noted previously (12, 18) and was confirmed in our study; its cause remains unclear.
Single and double chain preparations. The clinically effective dose used in our study was 0.875 mg/kg of single chain tissue plasminogen activator (G 11035) over 90 minutes. Previous studies of tissue plasminogen activator in acute myocardial infarction were performed with the two chain form of tissue plasminogen activator (G 11021). The effective dose over 90 minutes was 0.5 to 0.625 mg/kg. Concurrent with our study, the National Heart, Lung, and Blood Institute T1MI investigators (27) ascertained that this dose was less effective when one chain tissue plasminogen activator (G 11035) was used. Pharmacokinetic studies in primates and humans comparing GIl 021 with Gil 035 demonstrate that G11035 is cleared approximately 40% more quickly than is G 11021, and therefore a higher initial dose is necessary (Genentech, personal communication). However, this difference in pharmacokinetics is probably not due to differences in percent of one and two chain tissue plasminogen activator. When one chain is compared with to two chain tissue plasminogen activator derived from a portion of the same one chain tissue plasminogen activator, the pharmacokinetic variables are indistinguishable. At the doses employed in our trial, a high rate of recanalization was observed with a comparable degree of fibrinogen sparing as compared with the tissue plasminogen activator used at lower doses in earlier trials (6) (7) (8) (9) (10) .
Improved pharmacologic methods. Gold et a1. (18) recently showed that a prolonged, low dose infusion of tissue plasminogen activator is effective in sustaining infarct vessel patency without compromising hemostatic variables. Reocelusion was not systematically documented by a repeat catheterization in our study, but 13 (18%) of 69 patients had clinical and/or angiographic data, or both, to support reocelusion. None of the patients in our study received a prolonged, low dose maintenance tissue plasminogen activator infusion, which might have reduced this complication. Another important adjustment in dosing may be to administer even higher doses of tissue plasminogen activator during the first hour of therapy. Preliminary experience (28) with 90 mg over the first hour suggests that this is effective in reducing the time to recanalization. At the intravenous dosing utilized in this trial, the predominantly single chain preparation of tissue plasminogen activator proved to be a very effective agent in promoting coronary thrombolysis with relative sparing of fibrinogen. The future clinical trials in myocardial infarction and other thrombotic disorders may help to establish the optimal dosing of this preparation.
